Multi-event September 2018 FDA Recall Drug by Otsuka Pharmaceutical Development & Commercialization, Inc.

This Multi-event Class III drug recall was voluntarily initiated by Otsuka Pharmaceutical Development & Commercialization, Inc. on September 17, 2018 for the product Drug. The FDA reported the reason for recall as labeling not elsewhere classified. The product was distributed Nationwide and the recall is currently terminated.

Reported Recall Events

Recall Number: D-0017-2019

Reason for Recall
Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.
Initiated
09-17-2018
Reported
10-10-2018
Quantity
17325 kits

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Nationwide in the US
treatNOW ABILIFY (aripiprazole) and ABILIFY MAINTENA (aripiprazole) 400MG for extended release injectable suspension. Kit Contents: 2 packs ABILIFY Tablets 10mg (14 day supply) plus 1 ABILIFY MAINTENA Pre-filled Dual Chamber Syringe Kit. Rx only. Not for sale or reimbursement. Distributed and Marketed by: Otsuka America Pharmaceutical, Inc. Rockville, MD 20850. Marketed by: Deerfield, IL 60015 USA. Bar Code DCSKit-59148-10Tabs-01

Batch or Lot Expiration Information

Lot# Lots: 7F92YUD3H1A/AIS1017B, 7F92YUD3H1A/AIS1017C, EXP 30-Jun-2020.

Recall Number: D-0018-2019

Reason for Recall
Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.
Initiated
09-17-2018
Reported
10-10-2018
Quantity
4738 kits

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Nationwide in the US
treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectable suspension. Kit contents 2 packs Abilify Tablets 10 mg (14 day supply) plus 1 Abilfy Maintena Vial Kit.Rx only. Distributed and Marketed by: Otsuka America Pharmaceutical, Inc. Rockville, MD 20850 USA Marketed by: Lundbleck, Deerfield, IL 60015 USA Bar Code VialKit-59148-10Tabs-02

Batch or Lot Expiration Information

Lot# Lots: 7F92YUD3H1A/ACS1616B, EXP 31-Jul-2019; F92YUD3H1A/ACS0118C, EXP 30-Jun-2020.